Intrasense — Regulatory Filings 2019

Sep 24, 2019

Press release Montpellier, September 24th 2019 – 17h45 CEST

The new version of Myrian® 2.7 unveiled, many clinical innovations

Intrasense™ (FR0011179886 - ALINS), specialist in medical imaging software solutions and designer of Myrian®, is proud to present the version 2.7 of its visualization platform which includes many novelties as well as major clinical innovations.

Myrian® 2.7: innovation at the heart of the strategy

This new version of Myrian® brings many innovations, starting with ergonomics and interface which have been optimized to improve user experience, a central element of the solution. The use of Myrian® is becoming even more simpler and more intuitive, with the goal of matching with the specific needs of clinicians and healthcare professionals, enabling them to perform diagnostics safer and faster.

A brand-new mammography application

Myrian® 2.7 enriches the catalog of clinical applications with a new application dedicated to the visualization of mammography exams. XP-Mammo provides clinicians with essential tools for diagnosis while incorporating valuable functionalities for daily clinical workflow. This new clinical application, targeted to be used in the context of breast cancer screening, is very complementary to the existing XP-Breast application, one of the most successful applications of Myrian® platform dedicated to the identification and quantification of breasts lesions in MRI. Breast cancer is the most common cancer in women worldwide, one in nine women will develop breast cancer in their lifetime.

With this new clinical application, Intrasense™ is strengthening the positioning of its platform as a central and state-of-the-art solution for visualization and analysis of medical imaging.

XP-Cardiac and XP-Colon applications enriched with new features

Already present in the catalog, XP-Cardiac has benefited from a major update with new functionalities and key improvements like the automatic segmentation of the coronaries, the improvement of tools for the quantification of the stenosis, as well as tools for surgical planning.

The new version of XP-Colon also provides new features (filet view) and enhancements of existing tools to facilitate patient care and diagnosis by healthcare professionals.

Intrasense™ maintains a pace of two releases a year of new commercial versions of Myrian® platform to meet the ever-changing needs of clinicians and healthcare professionals. Version 2.7 will be presented at the end-of-year professional congresses, JFR (France), RSNA (USA), CMEF (China). The next version, currently under development (2.8) and containing complementary major new innovations, will be commercially available during the first half of 2020.

About Intrasense™

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner…). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr

Contacts

Intrasense Jérémy Peyron Marketing & Communication manager 1231 avenue du Mondial 98, 34000 Montpellier, FRANCE Tel: +334 67 130 130 investor@intrasense.fr

NewCap Investor Relations and Financial Communication Roxane Gbedigro

Tel: +331 44 71 94 94 intrasense@newcap.eu

Page 2/2